Calidi Biotherapeutics (CLDI) grants director 6,000 options vesting in 12 months
Rhea-AI Filing Summary
Calidi Biotherapeutics, Inc. (CLDI) reported that director Sanders Corazon (Corsee) D. received a grant of non-qualified stock options on August 17, 2026. The grant covers 6,000 options to purchase common stock at an exercise price of $1.36 per share, equal to the closing price on the grant date. These options vest and become exercisable in 1/12th monthly installments over one year, starting on the grant date, and expire on August 17, 2036. The options were granted under Calidi’s non-employee director compensation policy and issued pursuant to its 2023 Equity Incentive Plan. The reported post-transaction holding of 6,000 options reflects only this grant and does not include options previously granted to the director.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Sanders Corazon (Corsee) D.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Options (right to buy) F1, F2 | 6,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Options (right to buy) — 6,000 shares (Direct)
Footnotes (2)
- F1. On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
- F2. Does not include the stock options previously granted to the Reporting Person.
Key Figures
Options granted: 6,000 options
Exercise price: $1.36 per share
Underlying shares: 6,000 shares
+3 more
6 metrics
Options granted
6,000 options
Non-qualified stock options granted on August 17, 2026
Exercise price
$1.36 per share
Exercise price equal to closing price on grant date August 17, 2026
Underlying shares
6,000 shares
Common shares underlying the non-qualified stock options
Vesting schedule
1/12 per month over one year
Vests monthly starting on the August 17, 2026 grant date
Expiration date
August 17, 2036
Expiration of the non-qualified stock options grant
Post-transaction options reported
6,000 options
Direct holdings from this grant only; excludes previously granted options
Key Terms
Non-Qualified Stock Options, 2023 Equity Incentive Plan, non-employee director compensation policy, vest
4 terms
Non-Qualified Stock Options financial
"the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
2023 Equity Incentive Plan financial
"issued under the Issuer's 2023 Equity Incentive Plan"
non-employee director compensation policy financial
"granted pursuant to the Issuer's non-employee director compensation policy"
vest financial
"shall vest, and become exercisable, in 1/12th per month installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What equity award did CLDI director Sanders Corazon receive on August 17, 2026?
On August 17, 2026, the director received 6,000 non-qualified stock options to buy Calidi Biotherapeutics common stock. The options vest monthly over one year and were granted under the company’s non-employee director compensation policy and 2023 Equity Incentive Plan.
What is the exercise price of the new stock options granted by CLDI?
The new options have an exercise price of $1.36 per share, equal to the closing price on August 17, 2026. This price is the cost per share to exercise the 6,000 non-qualified stock options for Calidi Biotherapeutics common stock.
How do the CLDI stock options granted on August 17, 2026 vest?
The options vest in 1/12th per month over one year, beginning on the August 17, 2026 grant date. This schedule means the 6,000 non-qualified stock options become exercisable gradually in equal monthly installments throughout the year.
When do the Calidi Biotherapeutics (CLDI) options granted to the director expire?
The non-qualified stock options granted on August 17, 2026 expire on August 17, 2036. After this date, any unexercised portion of the 6,000 options to purchase Calidi Biotherapeutics common stock can no longer be exercised.
Are previously granted CLDI stock options to the director included in the reported post-transaction holdings?
No. A footnote states that the reported 6,000 options following the transaction do not include stock options previously granted. The Form 4 entry therefore reflects only this specific August 17, 2026 grant, not the director’s total option holdings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
